By TN Media News:
Riyadh, Saudi Arabia: Bayer, a leading global life sciences company, and Huma Therapeutics, a top digital health firm, have launched an innovative heart health risk assessment tool in Saudi Arabia. This is the first international rollout since the tool’s initial launch in the United States in 2023.
The Bayer Aspirin Heart Health Risk Assessment aligns closely with Saudi Arabia’s Vision 2030 healthcare transformation strategy, focusing on prevention and early detection of cardiovascular diseases (CVD).
A Game-Changer in Heart Health Screening:
The Heart Health Risk Assessment is a digital-only tool. It allows individuals to quickly check their 10-year risk of cardiovascular disease without the need for invasive procedures like blood tests or blood pressure readings.
Huma developed the tool’s algorithm using more than 15 years of longitudinal data from over 500,000 participants in the UK Biobank Dataset. Clinical validation through the European Society of Cardiology confirmed the tool’s high predictive accuracy compared to traditional screening methods.
Supporting Saudi Arabia’s Vision 2030 Goals:
The launch in Saudi Arabia supports the nation’s Vision 2030 healthcare objectives, which prioritize reducing the clinical and economic burden of heart disease. Cardiovascular conditions, such as stroke and heart failure, remain among the leading causes of death in the Kingdom.
Bayer shares a similar global mission: “Health for All, Hunger for None.” Through initiatives like this, Bayer is committed to advancing preventive heart care worldwide.
Additional Health Initiatives in Saudi Arabia:
Alongside this launch, Huma and Bayer are backing other health projects in the Kingdom:
-
Huma recently launched a diabetes care pathway through the Seha Virtual Hospital, a cutting-edge telemedicine platform by the Saudi Ministry of Health.
-
Bayer has pledged to screen 1 million Saudi citizens at risk of developing cardiovascular disease through the Protect Your Heart campaign, in collaboration with the Ministry of Health.
Embracing Biotechnology and Digital Health Innovation:
This launch is part of Saudi Arabia’s broader Biotechnology Strategy, which aims to use advanced technologies like digital health tools to improve healthcare outcomes.
Dan Vahdat, CEO and Founder of Huma, stated:
“Saudi Arabia is becoming a global leader in digital-first healthcare. Our software has recently achieved Saudi FDA Class C regulatory clearance, allowing us to support Vision 2030’s healthcare transformation. We are proud to help promote heart health at scale and look forward to further collaborations.”
Bayer’s Commitment to Preventive Care:
Mohamed Galal, Vice President of Middle East and Pakistan at Bayer, added:
“Cardiovascular disease is a major health challenge worldwide, and the Middle East is no exception. Bayer is committed to working with governments and partners to improve heart health through early detection and digital solutions.”
Maged ElShazly, Bayer’s Managing Director & Country Commercial Lead Consumer Health in Saudi Arabia, also commented:
“This partnership with Huma highlights Bayer’s focus on advancing digital health. The launch of the Heart Health Risk Assessment tool is a crucial step toward meeting the prevention goals of Vision 2030.”
Expanding Beyond Saudi Arabia:
Following this successful launch, Bayer and Huma plan to introduce the Heart Health Risk Assessment tool to Latin America in the coming year, continuing their mission to promote global heart health through innovation.
